Piper Sandler initiated coverage of BillionToOne (BLLN) with an Overweight rating and $150 price target The company has built a platform to capture targeted molecules at single count levels and remove artifacts before amplification, the analyst tells investors in a research note. Piper believes BillionToOne is in the early stages of using its approach for therapy selection and monitoring.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLLN:
- BillionToOne initiated with a Hold at Jefferies
- BillionToOne, Inc.: Strong Market Position and Profitability Justify Buy Rating
- BillionToOne’s Innovative Platform Poised for Growth in Reproductive Health and Oncology Markets
- BillionToOne’s Innovative Sequencing Platform and Strong Growth Prospects Justify Buy Rating and $150 Price Target
- Balanced Outlook on BillionToOne, Inc.: High Growth Potential Amidst Competitive Challenges